SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently experiencing heightened volatility following unsubstantiated claims by Michael Burry that Anthropics growth is cannibalizing Palantirs market share, a narrative that has triggered a sell-off among momentum-driven traders. While the broader community remains fiercely divided between those who view this as a temporary, algorithm-fueled reaction to fear-based headlines and those who see the pullback as a necessary correction for an overextended valuation, many long-term bulls are focusing on the company's solid fundamentals and the technical distinction between Anthropic's model-layer services and Palantir's integrated operational platform.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is experiencing a significant momentum-driven rally fueled by high-profile partnerships with Google and Musks Tesla/SpaceX, as well as optimistic sentiment around its foundry business and domestic manufacturing potential. Community discussions are dominated by bullish targets, debates over institutional re-pricing, and warnings regarding potential volatility for those chasing the current run-up.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing extreme volatility driven by a massive AI-fueled surge in NAND memory demand and optimistic analyst price target hikes, while the community remains sharply divided between bulls chasing momentum and bears calling for a bubble burst. Conversations are dominated by intense speculation over potential stock splits, concerns regarding the sustainability of parabolic growth, and the broader impact of geopolitical tensions on the semiconductor sector.

Maulcoin

Maulcoin is trending as an active community of supporters rallies behind the project despite ongoing technical challenges with ticker and chart integration on social platforms. Investors are leaning into the project's 'dark side' branding and transparent communication, viewing the current stage as an early accumulation opportunity while the community works toward formal exchange listings.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is currently seeing intense market volatility driven by polarizing debate over its growth potential versus high valuation, as investors weigh the stock's role in the photonics and AI hardware revolution against concerns about recent financial reports and insider selling. The community remains sharply divided, with bulls pointing to record order backlogs and hyperscaler demand, while bears focus on revenue misses and the potential for dilution to justify a significant pullback.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is currently facing significant selling pressure as investors grapple with concerns regarding AI's potential to disrupt traditional enterprise software models. Despite strong long-term fundamentals and recent insider buying, the community remains divided, with many debating whether the current price represents a generational buying opportunity or a signal of deeper structural headwinds for SaaS companies.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is seeing intense community debate as investors weigh concerns over subnet centralization and recent price volatility against its long-term potential as the "Bitcoin of AI." While some traders are liquidating positions due to broader market pressures and technical resistance, many long-term holders are actively utilizing dips to DCA and stake in the subnet ecosystem, viewing current price action as an accumulation phase.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake Inc. is currently facing heightened volatility as investors debate the impact of agentic AI advancements on its long-term software moat. While some market participants see the recent price drop as a value opportunity fueled by strong enterprise demand and revenue growth, others are actively betting against the stock, citing fears of market share erosion and the potential for AI to cannibalize traditional SaaS business models.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology is currently experiencing extreme volatility as traders speculate on a potential short squeeze, with community discussions heavily focused on comparing its recent price action to past "supernova" momentum runners. Market participants are debating the sustainability of these moves, frequently citing the stock's thin float and history of dramatic halts as they hunt for a breakout to triple-digit prices.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is currently the focal point of a intense debate between investors who view the recent sharp valuation compression as a generational buying opportunity versus those who fear that AI-driven disruption and headcount reduction at major tech firms signal a permanent shift away from traditional software licensing models. While the broader community is actively tracking technical support levels and potential Wyckoff accumulation patterns, significant sentiment remains divided between those interpreting the sector's weakness as a temporary overreaction to AI hype and those preparing for further downside as the sector navigates a structural re-rating.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Polaryx Therapeutics (NASDAQ:PLYX) Stock Price Down 1.9%  - Time to Sell?

Polaryx Therapeutics (NASDAQ:PLYX) Trading Down 1.9% - Time to Sell...

<ul class="summary-bullets"><li>Polaryx Therapeutics went public via a direct listing on Feb. 2.</li><li>The biotech firm is developing treatments for lysosomal storage disorders (LSDs).</li><li>Stocktwits sentiment for PLYX shifted to ‘extremely bullish’ after the stock rally.</li></ul><p>Shares of Polaryx Therapeutics (PLYX), a newly listed clinical-stage biotech firm, surged 70% on Tuesday,&nbsp;its best session on record, spurring increased interest from retail traders on Stocktwits. The micro-cap stock surged 29% on Monday.</p><h2 class="st-heading-2"><strong>Biotech Stocks Drawing Interest</strong></h2><p>Polaryx is focused on rare neurodegenerative diseases and is currently testing its PLX-200 treatment aimed at treating lysosomal storage disorders (LSDs), genetic diseases where the body can’t break down certain molecules, causing harmful buildup inside cells.</p><p>Biotech names have been catching investors' eyes as they seek shelter from the market turbulence triggered by the US-Israel conflict with Iran. Drug stocks have emerged as a go-to safe haven amid all the geopolitical uncertainty this year: the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF</a> (XBI) has gained over 4% this year while the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust</a> (SPY) and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust Series 1</a> (QQQ) index funds (which track the benchmark U.S. indices) have shed about 1%.</p><p>Polaryx’s pipeline includes four drug candidates, namely, PLX-200, PLX-100, PLX-300, and PLX-400 for LSDs. The last three are still in the preclinical stage.</p><h2 class="st-heading-2"><strong>Recent Updates From PLYX</strong></h2><p>The recent uptrend in the stock was likely triggered as investors took note of the company’s research advances. The company&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.nasdaq.com/articles/polaryx-initiate-soteria-phase-2-basket-trial-1h2026-stock?utm_source=chatgpt.com">announced</a> on Feb. 17 that it was moving forward with its phase-2 trial evaluating PLX-200 in four lysosomal storage disorders (LSDs) after receiving a “safe-to-proceed” letter from the Food and Drug Administration in October.</p><p>Last week, Maxim initiated coverage on the PLYX with a ‘Buy’ rating and $10 price target, which implies a 66% upside to the stock’s last close. The firm said it views PLX-200 as a differentiated offering, given its oral formulation and potential to address a broad spectrum of LSDs by targeting shared disease pathways.</p><h2 class="st-heading-2"><strong>Retail’s View On PLYX</strong></h2><p>On Stocktwits, retail sentiment for PLYX shifted to ‘extremely bullish’ as of early Wednesday, from ‘bullish’ the prior day, amid ‘extremely high’ message volume. The watcher count for&nbsp;<a href="https://stocktwits.com/symbol/PLYX">PLYX</a> on the platform increased nearly 50% over the past 24 hours.</p><p>Several users&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.stocktwits.com/NorthernMonkey1/message/647157001">said</a> they would be watching the stock in the coming days.</p><p>“$PLYX development stage biotech that traders tend to position in ahead of pipeline progress updates. These setups usually need sustained volume to get momentum going,” one trader&nbsp;<a href="https://stocktwits.com/topstockalerts/message/647155307">said</a>, explaining the prevailing view.</p><p>About 25 million PLYX shares exchanged hands on Tuesday, about nine times the stock’s average trading volume, according to Stocktwits data.</p><h2 class="st-heading-2"><strong>Stock Widely Down Since Listing</strong></h2><p>Polaryx’s recent gains come&nbsp;as a relief, as the stock slid sharply after its direct listing on the Nasdaq on Feb. 2. Shares currently trade at about one-tenth of their opening price of $45.00 that day.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oracle-shuts-up-the-bears-as-ceo-touts-faster-cheaper-ai-wall-street-is-totally-buying-it/cZdANc5RIJT">Oracle Shuts Up The Bears As CEO Touts 'Faster, Cheaper' AI: Wall Street Is Totally Buying It</a></p>

Traders work on the floor of the New York Stock Exchange.

Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest?

Watcher count for PLYX on Stocktwits increased by nearly 50% in a single day.

PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech

Equity

Watcher count for PLYX on Stocktwits increased by nearly 50% in a single day.


Maxim Group Begins Coverage on Polaryx Therapeutics (NASDAQ:PLYX)

Maxim Group began coverage on Polaryx Therapeutics in a report on Friday. They set a "buy" rating and a $10.00 price objective on the stock...

Polaryx Therapeutics (NASDAQ:PLYX) Shares Up 15.2% - Here's Why

Polaryx Therapeutics (NASDAQ:PLYX) Shares Up 15.2% - Here's Why...

What's Going On With Polaryx Therapeutics Stock Wednesday?

Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell after a surge due to a major clinical development announcement.read more...

Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans

Polaryx Therapeutics (NASDAQ: PLYX) shares rise on selecting research organization for SOTERIA trial to evaluate lead candidate for lysosomal storage disorders.read more...

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

PLYX
Polaryx Therapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest PLYX News

PLYXPolaryx Therapeutics Inc.